Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

BTOG 2022 Summer Meeting | The role of immunotherapy for the treatment mesothelioma

Riyaz Shah • 8 Jul 2022
BTOG 2022 Summer Meeting
Lung Cancer Mesothelioma
CheckMate 743

Riyaz Shah, BSc(Hons), MBBS, FRCP, PhD, Kent Oncology Centre, UK, discusses the role of immunotherapy for the treatment of patient with mesothelioma. The Phase III CHECKMATE-743 (NCT02899299) study highlighting the benefit of immunotherapy in the first-line setting. This interview took place at the BTOG 2022 Summer Meeting congress in London.

More from Riyaz Shah

3:17
Key insights from BTOG 2024: MARS 2 and HIT-MESO
Riyaz Shah • 18 Apr 2024
2:42
The benefits of immunotherapy versus chemotherapy: analyzing the results of the IPSOS trial
Riyaz Shah • 28 Apr 2023
2:35
CheckMate-816: what does the data tell us?
Riyaz Shah • 28 Apr 2023
2:49
SYSTEMS-2: radiotherapy in mesothelioma
Riyaz Shah • 28 Apr 2023

Related Videos

3:03
BTOG 2024 insights & future directions: a comprehensive approach to thoracic malignancies
Sanjay Popat • 19 Apr 2024
2:09
Is there a role for radiotherapy in extensive-stage SCLC?
Clive Peedell • 18 Apr 2024
3:03
BTOG 2024 insights & future directions: a comprehensive approach to thoracic malignancies
Sanjay Popat • 19 Apr 2024
1:03
The benefits of liquid biopsies for lung cancer in the community setting
Deepti Behl • 9 Apr 2024
The content of VJOncology is intended for healthcare professionals